NewsRoom Articles - Page 8 of 153 - PsychedelicNewsWire (PNW)

TuesdayJul 16, 2024 10:00 am

New Study Shows Psilocybin Cuts Cluster Headache Frequency in Half

Cluster headaches are headaches characterized by severe pain that often occurs on a side of the head or behind one eye. These headaches may last anywhere between 15 minutes to 3 hours and usually strike suddenly, often recurring more than once a day. The pain experienced by patients is often intense and is sometimes accompanied by other symptoms such as restlessness, nasal congestion and redness in the eye. Preliminary studies and anecdotal reports suggest that psilocybin may provide relief for this headache type. However, until now there wasn’t enough scientific evidence to back these claims. New research has determined that…

ThursdayJul 11, 2024 10:00 am

Studies Find Tripping, Microdosing Psilocybin Mushrooms Is Growing

Recently released reports suggest that hallucinogenic mushrooms may be the most popular psychedelic drug of choice for the public. The reports also determined that most individuals preferred microdosing over a full trip, with one study observing a 1,250% increase in internet search history on microdosing. The study, which also found that psilocybin searches began outpacing LSD in 2019, was conducted by epidemiologist Eric Leas. The study also determined that the increase in curiosity on microdosing correlated with changes in policies related to both psychedelics and marijuana. In his study, Leas observed that the more liberal a state became related to…

TuesdayJul 09, 2024 10:00 am

Study Highlights How Psilocybin Impacts Auditory Cortex, Causing Perception Changes

New research has generated new insights into how psilocybin influences the auditory cortex in mice models. Psilocybin is a natural psychedelic compound that is found in more than 200 species of fungi. The compound is known to induce altered states of consciousness when ingested, including changes in cognition, mood and perception. Various studies have investigated the compound’s effectiveness in treating mental-health disorders, including anxiety and depression. While its therapeutic potential is evident, the exact mechanisms via which this psychedelic alters perception and brain function aren’t well understood. Prior studies have shown that psilocybin alters activity patterns in the brain and…

TuesdayJul 02, 2024 10:00 am

CU Denver Unveils Psychedelic Research Center

The University of Colorado Denver recently launched the CU Denver Center for Psychedelic Research. This center is focused on improving the quality of life of individuals by conducting research on the potential benefits psychedelics may possess in the treatment of various mental, neurological, emotional and other health conditions as well as their possible use in the management of chronic, debilitating illnesses such as cancer. Professor Jim Grigsby, executive director and the center’s chief science officer, revealed that a national study was going on and the center was also planning a number of other studies. Grigsby, who teaches psychology at CU…

ThursdayJun 27, 2024 10:00 am

Older Psychedelics Users Reveal Fascinating Brain Function, Study Says

Scientific interest in psychedelics has increased greatly over the past few years as more and more trials determine that these substances possess the therapeutic potential to treat disorders such as post traumatic stress disorder (PTSD), depression or anxiety. Substances with the most promising results include LSD, psilocybin, MDMA and ketamine. Now, results from a recently conducted survey show that psychedelic drugs such as LSD, MDMA and psilocybin may help protect the brain from some features of aging. The survey was carried out in the United States and involved 3,294 adults, all aged between 42 and 92 years of age. The…

TuesdayJun 25, 2024 10:00 am

Analyzing Possible Industry Implications of FDA Advisory Panel Decision on MDMA

About a week ago, an advisory committee to the U.S. Food and Drug Administration (FDA) rejected evidence supporting the approval of MDMA as an alternative treatment for post-traumatic stress disorder (PTSD). This is a deflating moment for many in psychedelic research who have, for years, conducted trials on the drug in an effort to gain approval for commercial distribution. The application reviewed by the advisory committee was presented by Lykos Therapeutics, which concluded phase 2 and 3 trials investigating the effectiveness of MDMA-assisted therapy in managing post-traumatic stress disorder. In their report, the advisors revealed that they went through the…

ThursdayJun 20, 2024 10:00 am

UC Berkeley Research to Investigate How Psychedelics Alter People’s Views

Psychedelic fungi and plants have been used by various Indigenous communities in their healing and spiritual ceremonies for millennia. In the 1950s and 1960s, western therapists, psychiatrists and researchers began looking into whether these drugs could be used to manage mental-health conditions. However, the approval of the Controlled Substances Act halted this research, up until about a decade ago. Now, researchers at the UC Berkeley Center for the Science of Psychedelics are set to begin a study looking into how psychedelic substances shape how humans perceive things. Previous research has determined that the effects of these drugs on an individual’s…

TuesdayJun 18, 2024 10:00 am

Study Suggests Psychedelics Reduce Fear of Death by Impacting Metaphysical Beliefs

Therapeutic interest in psychedelics has grown as researchers learn more about the potential of these substances to manage the symptoms of different mental-health conditions and improve the well-being of individuals. Now, new research has determined that psychedelic experiences can cause a decrease in death anxiety, possibly by changing a person’s metaphysical beliefs. This discovery creates new approaches for understanding how these substances may help people deal with existential fears. For their study, researchers focused on determining if changes in core beliefs on consciousness and the nature of reality could be a key factor in decreasing death anxiety after psychedelics were…

ThursdayJun 13, 2024 10:00 am

Study Finds That Psychedelics, Religion Weaken Link to Risky Behavior and Violence

Classic psychedelics are drugs that induce altered states of consciousness and intense auditory and visual hallucinations when ingested. Common classic psychedelics include psilocybin, LSD, DMT and mescaline. These drugs have been used for centuries by Indigenous peoples in spiritual ceremonies and healing practices. In most countries, psychedelics are illegal. Despite their status, various studies have determined that these drugs hold promise in the treatment of conditions such as anxiety, depression and post-traumatic stress disorder (PTSD). Now, new research has determined that the link between violence and risky behaviors is weaker among individuals who report lifetime psychedelic use as well as…

TuesdayJun 11, 2024 10:00 am

Psychedelic Stocks Fall as Advisory Panel Tells FDA Not to Approve MDMA

A number of companies involved in the psychedelic space saw their stocks plummet during premarket trading earlier this week after an advisory panel counseled the U.S. Food and Drug Administration (FDA) against approving the use of MDMA as a treatment for post traumatic stress disorder (PTSD). MDMA, commonly known as molly or ecstasy, is a stimulant and psychedelic drug that comes in powder or pill forms. Currently, the drug is classified under Schedule I of the Controlled Substances Act, together with drugs such as LSD, marijuana, heroin and peyote. Drugs under this classification are said to have no accepted medical…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000